

**METHODS AND RESULTS** Patients included in a multicenter registry at 5 centers in Italy were systematically followed for major adverse cardiac events (MACE). Clinical data were obtained for 92 patients (mean age 57.1 years, 74.0% males) with a total of 95 lesions treated with overlapping Absorb BVS. Fifty-seven (61.9%) patients underwent scaffold implantation due to acute coronary syndrome. Diabetic patients were 17.3%. Multivessel disease was present in 63.0% of patients. Treated lesions were type B1 (21.3%), type B2 (23.0%), and type C (55.7%). Mean length covered by overlapping BVS was 48.0 ± 16 mm. The mean number of implanted Absorb BVS was 2.25 scaffolds per lesion and 2.63 scaffolds per patient. Angiographic and procedural success occurred in all patients. At a median follow up of 10 months (interquartile range, 5-14.75 months), cumulative occurrence of MACE was 4.34%. Adverse events were: 1 possible late scaffold thrombosis (unexplained cardiac death occurring two months after elective revascularization), 2 TLR due to BVS restenosis (documented BVS recoil in 1 case), 1 TVR due to restenosis of drug eluting stent proximal to two overlapped scaffolds.

**CONCLUSIONS** Our findings suggest that treatment of long lesions by means of overlapped Absorb BVS appears to be safe at mid-term follow up.

## DRUG ELUTING STENTS

### CRT-702

#### Composite Outcomes In 2.25-mm Drug Eluting Stents: A Meta-analysis And Systematic Review

Justin Z. Lee,<sup>1</sup> Nirmal Singh,<sup>1</sup> See-Wei Low,<sup>1</sup> Gilbert Ortega,<sup>1</sup> Uday Kanakadandi,<sup>1</sup> David Fortuin,<sup>2</sup> Tom Lassar,<sup>2</sup> Kwan S. Lee<sup>1</sup>

<sup>1</sup>University of Arizona, Tucson, AZ; <sup>2</sup>Mayo Clinic, Phoenix, AZ

**BACKGROUND** Percutaneous coronary intervention (PCI) of small vessels is associated with a high restenosis rate. Drug-eluting stents (DES) reduce restenosis in coronary arteries, but the role of DES in small coronary vessels has not been well defined. In our systematic review, we aim to summarize all known angiographic and clinical outcome of 2.25-mm DES, to highlight the need for specific outcome data in this cohort.

**METHODS** A systematic literature search of 394 relevant citations from PubMed, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials yielded 8 eligible studies studying FDA approved 2.25-mm DES. Angiographic and clinical outcome data were extracted and compared between each type of DES. Subgroup analysis comparing clinical outcome between sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) was done using a random effects model.

**RESULTS** Of the 8 studies included in the analysis, 6 were non-randomized and 2 were randomized against bare-metal stents (BMS). A total of 1,037 patients were studied, with follow-up ranging from 1 month to 5 years. PES, SES and everolimus-eluting stents (EES) were studied. Myocardial infarction at one year was highest in PES vs. SES and EES: 4.2% vs. 3.4% and 1.5%. Target vessel revascularization at one year was highest in PES vs. SES and EES: 13.8% vs. 5.7% and 8.8%. Death rate was highest in PES at 4.2% vs. SES and EES (3.4% and 1.5%). Mean late lumen loss for PES, SES, and EES was 0.28±0.11 mm, 0.15±0.11 mm, and 0.16±0.41 mm at 9 months to 1 year. Mean diameter stenosis for PES, SES and EES was 34.7±4.2%, 29.5±6.2%, and 20.9±22.5%. Mean binary stenosis for PES, SES and EES was 26.9±7.8%, 10.4±6.7%, and 9.6% respectively. No 2.25 mm specific data was available for zotarolimus eluting stents, which was reported in combination with larger stent sizes.

**CONCLUSION** Our composite data suggest that 2.25-mm SES and EES have superior clinical and angiographic outcomes compared with 2.25-mm PES, which has been shown to be superior to BMS in a randomized controlled study. Given the unique theoretical challenges posed by small vessel PCI, the overall lack of randomized data in this cohort needs to be addressed with future studies evaluating 2.25 mm stents in next-generation DES.

### CRT-703

#### Comparison of Biolimus A9-eluting Stent and Platinum Chromium Alloy Everolimus-eluting Stent in Patients with De Novo Coronary Artery Lesion: A Propensity Score-Matched Analysis

Seung-Woon Rha,<sup>1</sup> Byoung Geol Choi,<sup>1</sup> Se Yeon Choi,<sup>1</sup> Ji Young Park,<sup>2</sup> Sang-Ho Park,<sup>3</sup> Woong Gil Choi,<sup>4</sup> Soo Hyun Kim,<sup>4</sup> Eun-Gyu Lee,<sup>5</sup> Jihun Ahn,<sup>6</sup> Sang Yeub Lee,<sup>7</sup> Sang Min Kim,<sup>7</sup> Min Woong Kim,<sup>8</sup> Seong Gyu Yoon,<sup>9</sup> Tae Hoon Ahn,<sup>10</sup> Dong Joo Oh<sup>1</sup>

<sup>1</sup>Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea, Republic of; <sup>2</sup>Cardiology Department, Eulji General Hospital, Seoul, Korea, Republic of; <sup>3</sup>Cardiology Department, Soonchunhyang University Cheonan Hospital, Cheonan, Korea, Republic of; <sup>4</sup>Division of Cardiology, Konkuk University Chungju Hospital, chungju, Korea, Republic of; <sup>5</sup>Cardiovascular Center, Andong Sungso Hospital, Andong, Korea, Republic of; <sup>6</sup>Department of Internal Medicine, Soonchunhyang University Gumi Hospital, Gumi, Korea, Republic of; <sup>7</sup>Cardiovascular Center, Chungbuk National University Hospital, Cheongju, Korea, Republic of; <sup>8</sup>Department of Cardiology, Hanyang University Medical Center, Hanmaeum Hospital, Changwon, Korea, Republic of; <sup>9</sup>Department of Medicine, Korea University Graduate School, Seoul, Korea, Republic of; <sup>10</sup>Gachon University of Medicine and Science, Gil Hospital, Incheon, Korea, Republic of

**BACKGROUND** There have been limited data comparing efficacy and safety of Biolimus-eluting Stents (BES, Biomatrix™, Biosensors and Nobori™, Terumo) with Platinum Chromium Everolimus-eluting Stent (PtCr-EES, Promus Element™, Boston Scientific) in a series of Asian population in real world clinical practice.

**METHODS** A total of 626 patients (pts) receiving BES or PtCr-EES were pooled from our prospective percutaneous coronary intervention (PCI) registry from March 2008 to May 2013. To adjust potential confounders, a propensity score matched (PSM) analysis was performed using the logistic regression model, and clinical outcomes were compared between the two groups up to 12 months.

**RESULTS** After PSM analysis, 2 propensity-matched groups (149 pairs, n = 298 pts, C-statistic=0.793) were generated and the baseline characteristics of the two groups were balanced. Six to 9-month angiographic outcomes showed that the incidence of binary in-stent restenosis was higher in the BES group than PtCr-EES (18.9% vs. 7.0%, p=0.034). This adverse angiographic outcomes were translated into worse 12-month clinical outcomes; the incidence of target lesion revascularizations (TLR: HR; 3.879, C.I.; 1.06-14.2, p=0.041) and TLR-MACE (HR; 3.465, C.I.; 1.103-10.88, p=0.033) BA9 were significantly higher than PtCr-EES despite of similar incidence of mortality and myocardial infarction.

**CONCLUSIONS** As compared with PtCr-EES, BES seem to be associated with higher rate of TLR and TLR MACE up to 12-month in a series of Asian population in real world clinical practice.

**Table.** Mid-term angiographic and 12-month Clinical Outcomes after propensity score matched analysis

Variables, N (%)	Total (n=145)	BES (n=74)	EES-PtCr (n=71)	p Value
Six to 9 month angiographic outcomes				
Binary in-stent restenosis (≥50%)	19 (13.1)	14 (18.9)	5 (7.0)	0.034
Variables, N (%)	Total (n=298)	BES (n=149)	EES-PtCr (n=149)	p Value
One-year clinical outcomes				
Total death	9 (3.0)	5 (3.3)	4 (2.6)	ns
Cardiac death	4 (1.3)	2 (1.3)	2 (1.3)	ns
Myocardial infarction: MI	5 (1.6)	3 (2.0)	2 (1.3)	ns
ST segment elevation MI	1 (0.3)	1 (0.6)	0 (0.0)	0.316
Revascularizations	26 (8.7)	16 (10.7)	10 (6.7)	0.218
Target lesion: TLR	14 (4.6)	11 (7.3)	3 (2.0)	0.029
Target vessel: TVR	18 (6.0)	12 (8.0)	6 (4.0)	0.145
Non-Target vessel: NTVR	8 (2.6)	4 (2.6)	4 (2.6)	ns
Stent thrombosis	4 (1.3)	2 (1.3)	2 (1.3)	ns
Acute	1 (0.3)	0 (0.0)	1 (0.6)	
Subacute	1 (0.3)	0 (0.0)	1 (0.6)	
Late	2 (0.6)	2 (1.3)	0 (0.0)	
Total MACE	34 (11.4)	21 (14.0)	13 (8.7)	0.145
TLR MACE	17 (5.7)	13 (8.7)	4 (2.6)	0.025
TVR MACE	26 (8.7)	17 (11.4)	9 (6.0)	0.101

\*BES: Biolimus-eluting stent, EES: Everolimus-eluting stent, PtCr: Platinum chromium

### CRT-704

#### Ultra-Hydrophilic Stents Promote Early Healing and Minimize Late Tissue Response: A Potential Alternative to Second-Generation Drug Eluting Stents

Kumaran Kolandaivelu,<sup>1</sup> Lynn Bailey,<sup>2</sup> Stefano Buzzi,<sup>3</sup> Arik Zucker,<sup>3</sup> Algirdas Ziogas,<sup>4</sup> Vincent Milleret,<sup>4</sup> Martin Ehrbar,<sup>4</sup> Ahmed A. Khattab,<sup>5</sup> James R.L. Stanley,<sup>2</sup> Gee K. Wong,<sup>2</sup> Brett Zani,<sup>2</sup> Peter K. Markham,<sup>2</sup> Abraham R. Tzafriri,<sup>2</sup> Deepak L. Bhatt,<sup>1</sup> Elazer R. Edelman<sup>6</sup>

<sup>1</sup>Brigham and Women's Hospital, Boston, MA; <sup>2</sup>Concord Biomedical Sciences & Emerging Technologies (CBSET), Lexington, MA; <sup>3</sup>Qvanteq AG, Zurich, Switzerland; <sup>4</sup>University Hospital Zurich, Zurich, Switzerland; <sup>5</sup>Bern University Hospital, Bern, Switzerland; <sup>6</sup>Massachusetts Institute of Technology, Cambridge, MA

**BACKGROUND** Clinical trials and meta-analyses demonstrate the low restenosis and stent thrombosis risks of next generation drug eluting stents (DES). Co-evolution of device, delivery technique, and drug-related factors all contribute, yet relative advantages are difficult to surmise. On a background of optimized contemporary bare metal stents (BMS), we asked if locally eluted drugs are still as useful or if simple design changes might obviate need for drug, further enhancing performance, manufacturability, and cost.

**METHODS** We hypothesized that thin, bare metal cobalt chromium or platinum chromium stents modified with an ultra-hydrophilic surface (UHS) treatment could reduce late intimal hyperplasia (IH) with second-generation DES, yet maintain fast healing akin to bare metal stents (BMS). To test this, commercially available, FDA-approved DES and BMS were compared with UHS in A) porcine coronary models to assess IH and late thrombosis; and B) a rabbit iliac model to assess early healing and subacute thrombosis.

**RESULTS** *In vitro* tests demonstrated similar to faster endothelialization with reduced platelet adhesion (97% reduction, p<0.001) compared with untreated BMS. Hydrophilic treatment reduced IH in porcine coronary arteries relative to 3 corresponding BMS and DES platforms (2-3-fold reduction in 30-day angiographic restenosis; p<0.03). In contrast to early healing of UHS and BMS (porcine 30-day endothelialization score uniformly 4.0 of 4.0; confirmed in rabbit), DES trended to delayed healing at one month (range 2.67 to 4.0 out of 4.0) that resolved by 3 months, correlating with computed drug-receptor saturation. Elevation in thrombotic indices correlated with reduced endothelialization (p<0.0002) and occurred most often with DES, never with UHS (Poisson probability=0.135).

**CONCLUSION** Ultra-hydrophilic surface treatment of contemporary stents conferred excellent healing while moderating neointimal and thrombotic responses. With